Zevra Therapeutics, Inc. (ZVRA)

In November 2025, Zevra Therapeutics reported Q3 financial results with net revenue of $26.1 million, driven by MIPLYFFA, and announced that the EMA was reviewing the Marketing Authorisation Application for arimoclomol. In March 2026, Justin Renz was appointed as CFO. Zevra released its Q4 and Full Year 2025 earnings report, beating estimates with an EPS of $0.19 and revenue up $22.12 million, leading to a stock increase. The stock gained due to a partnership with GeneDx for a genetic testing program. BTIG initiated coverage with a Buy recommendation. Commave Therapeutics SA agreed to acquire a portfolio of Zevra's serdexmethylphenidate (SDX) including AZSTARYS and KP1077 for $50 million. Consensus EPS estimates fell, and an independent director exercised options to buy stock. Insiders have sold more stock than they have bought in the past three months.

There is no direct indication of demand seasonality for Zevra Therapeutics' products and services. The demand for their therapies is driven by the ongoing medical needs of patients with rare conditions rather than seasonal fluctuations.

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited treatment options. The company operates in the Healthcare sector, specifically in Biotechnology and Pharmaceutical Preparation Manufacturing. Zevra's mission is to address unmet medical needs in the rare disease community through science, data, and patient focus. Its commercial products include MIPLYFFA for Niemann-Pick disease type C, OLPRUVA for urea cycle disorders, and AZSTARYS for ADHD. The company's pipeline includes KP1077 for idiopathic hypersomnia and narcolepsy, and Celiprolol for vascular Ehlers-Danlos syndrome.

Zevra Therapeutics has a global presence with its headquarters in Boston, Massachusetts, and corporate offices in Celebration, Florida, and Frederiksberg, Denmark. The company is expanding its global footprint through partnerships in Europe and Asia, contributing to research insights, diversified patient populations for clinical trials, and future product launches. Zevra is focused on expanding access to its therapies in both U.S. and European markets.

Zevra Therapeutics has a reputation as a patient-centric company focused on providing life-changing therapeutics for rare diseases. The company emphasizes its commitment to addressing unmet medical needs and collaborating with key thought leaders, physicians, patients, care partners, and advocacy groups. The successful commercial launch of MIPLYFFA has positively contributed to its reputation.

Zevra Therapeutics has a diverse ownership structure. Institutional shareholders hold 64.97% of the stock, Zevra Therapeutics insiders own 21.95%, and retail investors hold 13.08%. Major institutional owners include BlackRock, Inc., Woodline Partners LP, and Vanguard Group Inc. Individual insider owners include Samuel J. Braun and Christal M. M. Mickle.